# US 10,478,394 B2 · Compositions and methods to promote wound healing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,394 B2
- Document ID: US10478394B2
- Status: Granted
- Kind: B2
- Application number: 15/557,407
- Filed: 2016-03-10
- Published: 2018-04-26
- Granted: 2019-11-19
- Earliest claimed: 2015-03-11
- Assignees: Wayne State University
- Applicants: Wayne State University
- Inventors: Fu-Shin X. Yu
- Web page: https://patentgrep.com/patent/US10478394B2

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 47/02: Inorganic compounds
- A61K 47/38: Cellulose; Derivatives thereof
- A61L 15/18: containing inorganic materials
- A61L 15/28: Polysaccharides or their derivatives {(A61L15/225 takes precedence)}
- A61L 15/44: Medicaments
- A61L 15/60: Liquid-swellable gel-forming materials, e.g. super-absorbents
- A61L 26/0066: {Medicaments; Biocides}
- A61L 26/008: {Hydrogels or hydrocolloids}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- C07K 14/545: IL-1
- A61L 2300/414: Growth factors
- A61L 2300/426: Immunomodulating agents, i.e. cytokines, interleukins, interferons
- A61L 2300/432: Inhibitors, antagonists (A61L2300/402 - A61L2300/43 take precedence)
- A61L 2300/436: of receptors
- A61L 2430/32: for nerve reconstruction
- A61L 2430/34: for soft tissue reconstruction
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1B) receptor antagonist (IL-1Ra), such as anakinra.

## Claims

### Claim 1

A method of promoting healing of a chronic wound in a diabetic subject comprising administering to the chronic wound a therapeutically effective amount of a gel comprising a therapeutic agent consisting of a therapeutic protein consisting of the sequence provided in SEQ ID NO: 26 (anakinra), thereby promoting healing of the chronic wound.

### Claim 2 (depends on 1)

The method of claim 1, wherein the chronic wound is a diabetic ulcer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the administering is topically administering.

### Claim 4 (depends on 1)

The method of claim 1, further comprising applying a wound dressing to the wound.

### Claim 5 (depends on 4)

The method of claim 4, wherein the administering and applying are achieved in one step.

### Claim 6 (depends on 4)

The method of claim 4, wherein the wound dressing is an adhesive bandage.

### Claim 7 (depends on 1)

The method of claim 1 further comprising administering a platelet-derived growth factor and/or Becaplermin.